protein synthesis and replication. [6] [7] [8] [9] While strong evidence supports the beneficial effect of sirolimus in OT, its effect in allo-HSCT recipients is less conclusive and remains a matter of debate. [10] [11] [12] [13] [14] OT and allo-HSCT procedures differ in many aspects. For instance, higher sirolimus blood concentrations are targeted in OT recipients (12-20 ng/mL) compared to allo-HSCT recipients (3-15 ng/ mL) during maintenance therapy. [10] [11] [12] [13] [14] Allo-HSCT is also characterized by shorter sirolimus exposure times (the scheduled reduction of immunosuppressant drugs promotes the immunotolerance phenomena), the more common use of drugs with potential drug-drug interactions (ie, triazoles), and with conditions related to variable absorption capacities (mucositis, nausea, vomiting, and/or diarrhea associated with conditioning regimens, drugs, or graft-versus-host disease [GvHD] ) that produce large concentration fluctuations and/ or treatment interruptions. It is not known whether these factors distort the consistency of anti-CMV sirolimus activity in allo-HSCT recipients. Exposure-response analyses are of utmost importance because exposure variability results in different anti-CMV activity patterns for different drugs. [15] [16] [17] For example, maribavir studies
showed that low doses failed to prevent CMV-I, 18 while higher doses showed encouraging anti-CMV activity. 19 With regard to response evaluation, CMV DNAemia is an interesting target for efficacy studies. However, CMV DNAemia is a common and complex phenomenon after allo-HSCT (>70% of the recipients) 4, 12 and its analysis is particularly challenging. CMV DNAemia is characterized by an unpredictable and alternating "transient status" (ie, periods where it may be detectable or undetectable) in which viral loads and episode lengths are highly variable. 12, 20 The complexity of CMV DNAemia kinetics leads to the use of complex and innovative statistical models derived from the field of pharmacokinetics and pharmacodynamics if data are to be analyzed. From among these tools, the compartmental continuous-time Markov model considers time as a continuous variable, hence eliminating the need for equally spaced CMV DNAemia states observations over time, as required in ordinary Markov or discrete-type models. 21, 22 This approach could be useful to describe the CMV DNAemia data available from daily clinical practice, considering viral load values as a dichotomous outcome (detectable or undetectable). This methodology could also be useful for quantifying the effect of drug trough concentrations in CMV DNAemia over time. To the best of our knowledge, the inhibitory effect of sirolimus on CMV at different exposure levels remains unexplored. Therefore, in this study, we developed a continuous-time Markov model to estimate the probability of different CMV-DNAemia states (detectable/ undetectable) in a cohort of allo-HCST recipients. We also explored the potential exposure-response relationship between sirolimus concentrations and CMV DNAemia over time.
| PATIENTS AND ME THODS

| Patients
This study included 53 consecutive reduced-intensity conditioning-allo-HSCT recipients at risk of CMV reactivation who received sirolimus and tacrolimus-based (Sir-Tac) GvHD prophylaxis between 
| Conditioning regimen and GvHD prophylaxis
As described elsewhere, 23 we used 3 different conditioning regimens:
(1) 150 mg/m 2 fludarabine in combination with 140 mg/m 2 melphalan, 
| Sirolimus and tacrolimus blood level monitoring and technical considerations
The sirolimus and tacrolimus trough blood levels were monitored at least twice a week for the first 4 weeks after transplantation or until discharge, then once a week until day +100, and thereafter at each outpatient visit using an Abbott Laboratories Architect i-System (Abbott Park, IL, USA). 25 All the blood samples collected were at trough concentrations just prior to patients receiving a scheduled dose. Doses were titrated to achieve the target blood concentrations of 5-12 ng/mL for sirolimus and 5-10 ng/mL for tacrolimus.
| Cytomegalovirus monitoring and cytomegalovirus infection management
We monitored the CMV DNA load in plasma at least once a week for the first 100 days after stem cell infusion and thereafter, at each outpatient visit. From October 2008 to May 2012 the plasma CMV DNA load was quantified using a CMV real-time polymerase chain reaction (PCR) kit (produced by Qiagen GmbH, Hilde, Germany for Abbott Molecular Diagnostics) and antiviral therapy was initiated when the CMV DNA load exceeded 500 copies/mL. From May 2012, we used a Real Time CMV PCR assay (Abbott Molecular, Des
Plaines, IL), as previously described. 12, 20 Preemptive antiviral therapy was initiated upon detection of >1500 IU/mL (>500 copies/mL with the Abbott PCR kit and >1000 copies/mL with the Real-Time CMV assay) or when the CMV DNA doubling time was 2 days or less, whichever came first. 20, 26 The detection limit of both these PCR as- 
| Structural continuous-time Markov model
A Markov process is a stochastic process in which future states depend on the present state. In this study, a continuous-time Markov model was developed to describe the probability of transition between CMV DNAemia states (CMVs). Data were analyzed by nonlinear mixedeffects modeling using the LAPLACE method in NONMEM software where k a and k d are the CMV activation and deactivation first-order rate constants that control the compartmentalized system described in Figure 1 , and t is the time since the last observation. As noted in these equations, probabilities reach a steady state after enough time has passed since last observation and thus Equation 1 can be transformed into Equation 3 to describe probability in steady state.
In this study, all the patients began in an initial state of undetectable CMV DNAemia. Therefore, the compartment describing P(CMVs = 0) was initiated at a value of 1, and the compartment describing the P(CMVs = 1) was initiated with a value of 0. After each observation, the compartmental system was re-initiated so that after a detectable CMV DNAemia episode was observed, the probabilities were set to P(CMVs = 1) = 1 and P(CMVs = 0) = 0, and after an undetectable CMV DNAemia test result was recorded, the probabilities were set to P(CMVs = 1) = 0 and P(CMVs = 0) = 1. By resetting the system after each observation, the probability of transitioning from 1 CMV DNAemia state to the other is conditioned both on the last observation state and the time elapsed since that observation. As an illustrative example, Figure 2 shows a representation of the evolution of the probabilities over time. Interindividual variabilities were considered in the development of this model following a log-normal distribution. CMV-positive recipient and CMV-negative donor. Regarding Sir-Tac concentrations, linear, exponential, and E max models were tested to (1) 
| Covariate analysis
P CMVs = 1 (t) = k a k a + k d + k d k a + k d ⋅ e −(k a +k d )⋅t (2) P CMVs = 0 (t) = 1 − p CMVs = 1 (t) (3) P CMVs = 1 ss = k a k a + k d F I G U R E 1 CMV-
| Final model evaluation
The nonparametric bootstrap resampling technique was used to validate the reliability of the parameters of the final model. One thousand bootstrap replicates were generated by random resampling the original dataset with replacement. The predictive performance of the final model was evaluated through a visual predictive check.
In order to do this, 200 simulations of a study with the same design as the original study were performed using the final model. Then, simulated outcomes were compared visually with observed data.
Data records were divided into bins depending on sirolimus concentrations. Then, the probability of CMV-DNAemia being detectable given a previous undetectable CMV-DNAemia was computed as the fraction of patients with undetectable CMV-DNAemia experiencing this transition. The model was considered adequate if observed data were included inside the 90% confidence interval of simulated data.
Finally, a sensitivity analysis was performed to evaluate the significance of sirolimus effect on the risk of CMV reactivation. To accomplish this, 1000 simulations of CMV-seropositive recipients with CMV-seronegative donors and tacrolimus concentrations of 0 ng/ mL were performed considering the variance-covariance matrix of the final model for increasing sirolimus concentrations. Simulated model parameters were used to compute the probability of CMVDNAemia being detectable 100 days after the last undetectable CMV-DNAemia observation.
| RE SULTS
| Patient characteristics and transplant outcomes
The disease and transplant characteristics and outcomes of the patient cohort are summarized in Table 1 . The series included allo-HSCT recipients with a high risk of CMV reactivation because most patients (81%) were allografted from an unrelated donor (URD) and 21% had a HLA mismatch with the donor and consequently received ATG as part of their conditioning treatment. In addition, almost half of the recipients (n = 24, 45%) received hematopoietic stem cells from a CMV-seronegative donor.
| Cytomegalovirus DNAemia, CMV-D characteristics, and risk factors
Data regarding CMV-DNAemia, CMV-DNAemia-RAT, and CMV-D are shown in Table 2 aGvHD, acute graft versus host disease; ATG, anti-thymoglobulin; ASCT, autologous hematopoietic stem cell transplantation; Bu, busulfan; CI, confidence interval; CMV, cytomegalovirus; c-GHVD, chronic graft versus host disease; CR, first complete remission; CMV DNAemia-RAT, cytomegalovirus DNAemia requiring antiviral therapy Cum Inc., cumulative incidence; D, donor; DFS, disease free survival; Flu, fludarabine; F-Up, follow-up; HCT-CI, hematopoietic cell transplant comorbidity index; Mel, melphalan; PROG, nonresponders or progression before allogeneic SCT with reduced-intensity conditioning; PR, partial response before allogeneic SCT with reducedintensity conditioning; CR, complete remission before allogeneic SCT with reduced-intensity conditioning; GvHD, graft-versus-host disease; NRM, non-relapse mortality; OS, overall survival; R, receptor; SD, stable disease; TT, thiotepa; y, year.
TA B L E 1 (Continued)
TA B L E 2 CMV-DNAemia test characteristics
Variables
Patients (n = 53)
Number of patients with detectable CMVDNAemia, n (%)
(94%)
Median peak CMV load during the first CMV-DNAemia episode, copies/mL (range) 
| Continuous-time Markov model
The probabilities of detectable and undetectable CMV-DNAemia at any time point were adequately described using a Markov model with a compartmental structure using differential equations (Figure 4 ). At this stage, 3 covariates were identified to significantly influence the activation rate constant (k a ): (1) recipient/donor CMV serostatus, (2) tacrolimus exposure, and (3) sirolimus exposure. CMV-seropositive recipients with CMV-seronegative donors had significantly higher k a -and thus a higher probability of transition to detectable CMVDNAemia state-as compared to other recipients/donors.
| CMV serostatus combinations
A linear model was used to describe the effect of tacrolimus on k a . A negative exponential model was used to describe the effect of sirolimus on k a , preventing k a, values from becoming negative at high sirolimus concentrations. These models were implemented as shown in Equation 4: where k a is the activation rate constant, k a_0 is the activation rate constant when tacrolimus and sirolimus concentrations are 0, θ T is the parameter quantifying the effect of tacrolimus concentration, C T is the concentration of tacrolimus, θ S is the parameter quantifying the effect of sirolimus concentration, and C s is the concentration of sirolimus.
The effect of increasing tacrolimus and sirolimus trough concentrations in the probability of detectable CMV-DNAemia is shown in Figure 5 . Higher tacrolimus trough concentrations were associated with a higher probability of detectable CMV-DNAemia. In contrast, higher sirolimus trough concentrations were associated with a lower probability of detectable CMV-DNAemia.
Final model parameter estimates as well as bootstrap results are shown in Table 3 . Visual predictive check plots show a good predictive performance of the developed model ( Figure 5) . Finally, the sensitivity analysis showed that sirolimus exposure between 0 and 6 ng/ mL has no or negligible effect on CMV-DNAemia while levels >8 ng/ mL significantly decreased the number of CMV-DNAemia observations (the risk ratios decreased from 0.68 to 0.21 when whole blood sirolimus concentrations changed from 8 to 18 ng/mL, P < .01), as shown in Figure 6 .
| D ISCUSS I ON
Here we report the first clinical evidence of a relationship between sirolimus exposure and the risk of having detectable CMV DNAemia after long-term follow-up in a cohort of allo-HSCT recipients with a very high risk of CMV reactivation. Importantly, our analyses tested a range of sirolimus concentrations (8-18 ng/mL) and clearly showed a significant reduction in the risk of detectable CMV-DNAemia at this dose range. The maximum simulated sirolimus concentration was set to 18 ng/mL since this represented a 50% increase as compared to the upper limit of the therapeutic range. Higher concentrations were not explored due to potential safety concerns. F I G U R E 5 Effect of increasing tacrolimus (left) and sirolimus (right) trough concentrations on the mean probability of detectable CMVDNAemia. The concentrations of sirolimus were fixed to 0 ng/mL when evaluating the effect of tacrolimus whole blood concentrations. The concentrations of tacrolimus were fixed to 0 ng/mL when evaluating the effect of sirolimus whole blood concentrations [Color figure can be viewed at wileyonlinelibrary.com]
This study presents several novelties. Firstly, CMV-DNAemia was used as an efficacy endpoint, avoiding the subjectivity associated with the use of different CMV-DNAemia-RAT arbitrary cutoff thresholds. 32 Secondly, we analyzed CMV DNAemia states as a continuum, in contrast to several classical CMV studies that focused on surveying CMV at the time of its first detection. Lastly, our model considers CMV DNAemia states (detectable or undetectable), irrespective of whether they are related to an initial or recurrent episode. This provides novel insight into the phenomenon of CMV DNAemia, allowing us to estimate the effect of sirolimus exposure on the probability of patients transitioning to a detectable CMV DNAemia state over time.
The fact that there was a high incidence (94%) of CMV DNAemia in this study may call into question the utility of sirolimus for preventing CMV viremia. However, we demonstrated that sirolimus had an independent and significant effect on CMV DNAemia states in multivariate model by reducing the probability of detectable CMV DNAemia. Our findings are also supported by in vitro models that demonstrate the role of mTOR signaling pathways in CMV protein synthesis [6] [7] [8] [9] [33] [34] [35] [36] and the potent inhibition of CMV replication exerted by sirolimus. 9, 35 Moreover, several factors may have contributed to this high incidence, including our very high-risk cohort (81% were transplanted from URDs and 45% from CMV-seronegative donors) and the effect of tacrolimus exposure in CMV DNAemia, which likely lessened the anti-CMV effect of sirolimus. Also, CMVDNAemia was observed early after transplantation (occurring at a median of 35 days, Table 2 ) and it is likely that sirolimus requires a longer time to achieve an optimal protective effect. In fact, a more prolonged exposure to sirolimus may have contributed to identifying a significant inhibitory effect of sirolimus on CMV viremia. In this sense, only half of the recipients (49%) eventually developed CMV-DNAemia-RAT. Also, we previously observed a similar CMVDNAemia incidence, but significantly lower CMV DNAemia-RAT occurrence, in allo-HSCT recipients on Sir-Tac compared to cyclosporine and methotrexate GvHD prophylaxis. 12 Therefore, considering that this study has identified an inhibitory effect of sirolimus on CMV, the question that arises is why the evidence for this anti-CMV effect is less consistent in allo-HSCT than in OT recipients. In this regard, sirolimus exposure may be important; here we provide the first clinical evidence for an association between sirolimus exposure and the probability of detectable CMV-DNAemia events. Our findings are supported by in vitro experiments, which show that sirolimus strongly inhibits the expression of the late-phase viral protein pUL-44 in an inverse concentrationdependent manner. 9 However, another substantial difference between allo-HSCT and OT clinical trials that may help to explain such a different anti-CMV activity is that sirolimus is usually compared to tacrolimus in the latter, whereas sirolimus is always combined with tacrolimus in allo-HSCT studies. Of note, we found that increased levels of tacrolimus were independently related to higher risk of CMV-DNAemia. The fact that these drugs have an opposing effect on CMV-DNAemia suggests that CMV viremia control in this study was not exclusively dependent on mTOR inhibition. Tacrolimus is known to impair T cell function, 37 whereas sirolimus has a role in the immune-mediated T cell response by regulating CD8+ memory T cell formation, enhancing specific CD8+ T cells. [38] [39] [40] [41] [42] Thus, the response of CMV-specific T cells likely played a major role in CMV viremia control, even in the context of antiviral prophylaxis. 43 Accordingly, we also observed in the multivariate model that CMV-positive recipients allografted from CMV-seronegative donors have a higher risk of detectable CMV-DNAemia observations. This observation also supports the major role of CMV-specific reconstitution of T cells in CMV control, since T cell reconstitution is certainly delayed in recipients with CMV-seronegative donors. 44 A notable result of this research is the identification of a range of sirolimus concentrations (8-18 ng/mL) with a maximal anti-CMV effect. These data are important since they provide a rationale to prospectively compare the safety and efficacy of sirolimus at different targeted range levels in the allo-HSCT setting, not only in terms of GvHD prevention but also for CMV protection. To the best of our knowledge, no comparative studies have previously analyzed the safety of high sirolimus levels in allo-HSCT. High sirolimus exposure was not related to impaired renal function after allo-HSCT F I G U R E 6 Sensitivity analysis for the effect of sirolimus concentrations on the probability of detectable CMV-DNAemia by quantitative PCR test. Risk ratio: ratio between the probability of CMV reactivation after 100 days for patients exposed to sirolimus concentrations as compared to patients exposed to sirolimus 0 ng/mL (Reference). Points represent median values. Horizontal lines represent 95% confidence intervals. CMV, cytomegalovirus; PCR, polymerase chain reaction [Color figure can be viewed at wileyonlinelibrary.com] in our prior experience. 23 However, 1 retrospective study showed that concentrations >10 ng/mL up to day +14 after stem cell infusion (not afterwards) resulted in a higher risk of transplant-associated microangiopathy when combined with tacrolimus. 45 Although an increase in sirolimus levels appears to be an attractive option to control CMV-DNAemia, nevertheless, such an increase could lead to relevant dose-dependent side effects such as hypercholesterolemia and hypertriglyceridemia, cardiovascular risk, mTOR-I-associated edema, and proteinuria with impaired glomerular filtration rate that should be monitored and controlled by lowering sirolimus doses when deemed appropriate. Alternatively, the reduction of tacrolimus levels, if possible, should also be considered as a valuable option for CMV control.
Finally, this study has certain limitations, including its retrospective nature and the reduced number of patients it includes.
In addition, given the relatively small number of patients and the long study duration, it is likely that the effect on CMV of factors such as the quality and quantity of anti-CMV T cell reconstitution over time, the length of active GvHD, and the type and duration of concurrent immunosuppressant drugs to control moderate to severe GvHD have been underestimated in our analyses.
However, our pharmacometric analysis allowed us to design a fitfor-purpose model, able to simultaneously consider patient and 
D I SCLOS U R E
The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation.
AUTH O R CO NTR I B UTI O N S
Authors who were responsible for the conception and the design of the 
R E FE R E N C E S
